202 related articles for article (PubMed ID: 33050159)
1. Targeting
Alcalá S; Mayoral-Varo V; Ruiz-Cañas L; López-Gil JC; Heeschen C; Martín-Pérez J; Sainz B
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050159
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological targeting of the receptor ALK inhibits tumorigenicity and overcomes chemoresistance in pancreatic ductal adenocarcinoma.
Parejo-Alonso B; Royo-García A; Espiau-Romera P; Courtois S; Curiel-García Á; Zagorac S; Villaoslada I; Olive KP; Heeschen C; Sancho P
Biomed Pharmacother; 2023 Feb; 158():114162. PubMed ID: 36571997
[TBL] [Abstract][Full Text] [Related]
3. The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma.
Begum A; Ewachiw T; Jung C; Huang A; Norberg KJ; Marchionni L; McMillan R; Penchev V; Rajeshkumar NV; Maitra A; Wood L; Wang C; Wolfgang C; DeJesus-Acosta A; Laheru D; Shapiro IM; Padval M; Pachter JA; Weaver DT; Rasheed ZA; Matsui W
PLoS One; 2017; 12(7):e0180181. PubMed ID: 28692661
[TBL] [Abstract][Full Text] [Related]
4. Targeting autophagy in pancreatic cancer: The cancer stem cell perspective.
Troumpoukis D; Papadimitropoulou A; Charalampous C; Kogionou P; Palamaris K; Sarantis P; Serafimidis I
Front Oncol; 2022; 12():1049436. PubMed ID: 36505808
[TBL] [Abstract][Full Text] [Related]
5. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract][Full Text] [Related]
6. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity.
Lai SW; Bamodu OA; Tsai WC; Chang YM; Lee WH; Yeh CT; Chao TY
Clin Exp Metastasis; 2018 Oct; 35(7):663-677. PubMed ID: 29987671
[TBL] [Abstract][Full Text] [Related]
7. The Anthrax Toxin Receptor 1 (ANTXR1) Is Enriched in Pancreatic Cancer Stem Cells Derived from Primary Tumor Cultures.
Alcalá S; Martinelli P; Hermann PC; Heeschen C; Sainz B
Stem Cells Int; 2019; 2019():1378639. PubMed ID: 31191663
[TBL] [Abstract][Full Text] [Related]
8. Src kinase inhibition restores E-cadherin expression in dasatinib-sensitive pancreatic cancer cells.
Dosch AR; Dai X; Gaidarski Iii AA; Shi C; Castellanos JA; VanSaun MN; Merchant NB; Nagathihalli NS
Oncotarget; 2019 Feb; 10(10):1056-1069. PubMed ID: 30800218
[TBL] [Abstract][Full Text] [Related]
9. Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma.
Yang W; Meng L; Chen K; Tian C; Peng B; Zhong L; Zhang C; Yang X; Zou J; Yang S; Li L
Cancer Sci; 2019 Apr; 110(4):1408-1419. PubMed ID: 30618127
[TBL] [Abstract][Full Text] [Related]
10. The Src family kinase inhibitors PP2 and PP1 effectively block TGF-beta1-induced cell migration and invasion in both established and primary carcinoma cells.
Bartscht T; Lehnert H; Gieseler F; Ungefroren H
Cancer Chemother Pharmacol; 2012 Aug; 70(2):221-30. PubMed ID: 22699812
[TBL] [Abstract][Full Text] [Related]
11. A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells.
Zhang J; He DH; Zajac-Kaye M; Hochwald SN
Cell Cycle; 2014; 13(19):3143-9. PubMed ID: 25486573
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.
Trevino JG; Summy JM; Lesslie DP; Parikh NU; Hong DS; Lee FY; Donato NJ; Abbruzzese JL; Baker CH; Gallick GE
Am J Pathol; 2006 Mar; 168(3):962-72. PubMed ID: 16507911
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib blocks transcriptional and promigratory responses to transforming growth factor-beta in pancreatic adenocarcinoma cells through inhibition of Smad signalling: implications for in vivo mode of action.
Bartscht T; Rosien B; Rades D; Kaufmann R; Biersack H; Lehnert H; Gieseler F; Ungefroren H
Mol Cancer; 2015 Nov; 14():199. PubMed ID: 26588899
[TBL] [Abstract][Full Text] [Related]
14. CCDC88A, a prognostic factor for human pancreatic cancers, promotes the motility and invasiveness of pancreatic cancer cells.
Tanouchi A; Taniuchi K; Furihata M; Naganuma S; Dabanaka K; Kimura M; Watanabe R; Kohsaki T; Shimizu T; Saito M; Hanazaki K; Saibara T
J Exp Clin Cancer Res; 2016 Dec; 35(1):190. PubMed ID: 27919290
[TBL] [Abstract][Full Text] [Related]
15. Desmoglein 3 contributes to tumorigenicity of pancreatic ductal adenocarcinoma through activating Src-FAK signaling.
Abula Y; Su Y; Tuniyazi D; Yi C
Anim Cells Syst (Seoul); 2021; 25(3):195-202. PubMed ID: 34262662
[TBL] [Abstract][Full Text] [Related]
16. The Ever-Evolving Concept of the Cancer Stem Cell in Pancreatic Cancer.
Valle S; Martin-Hijano L; Alcalá S; Alonso-Nocelo M; Sainz B
Cancers (Basel); 2018 Jan; 10(2):. PubMed ID: 29373514
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Thibault B; Jean-Claude B
J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
[TBL] [Abstract][Full Text] [Related]
18. The Src family kinase inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors.
Ungefroren H; Sebens S; Groth S; Gieseler F; Fändrich F
Curr Cancer Drug Targets; 2011 May; 11(4):524-35. PubMed ID: 21395548
[TBL] [Abstract][Full Text] [Related]
19. c-Src regulates constitutive and EGF-mediated VEGF expression in pancreatic tumor cells through activation of phosphatidyl inositol-3 kinase and p38 MAPK.
Summy JM; Trevino JG; Baker CH; Gallick GE
Pancreas; 2005 Oct; 31(3):263-74. PubMed ID: 16163059
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.
Winiarska M; Bojarczuk K; Pyrzynska B; Bil J; Siernicka M; Dwojak M; Bobrowicz M; Miazek N; Zapala P; Zagozdzon A; Krol M; Syta A; Podszywalow-Bartnicka P; Pilch Z; Dabrowska-Iwanicka A; Juszczynski P; Efremov DG; Slabicki M; Zenz T; Le Roy A; Olive D; Rygiel TP; Leusen JH; Golab J
MAbs; 2014; 6(5):1300-13. PubMed ID: 25517315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
